Expression of c-myc, c-Ha-ras1, and c-erbB-2 proto-oncogenes in normal and malignant human breast epithelial cells.
Short-term cultures of normal human mammary epithelial cells were used to determine the extent to which c-myc, c-Ha-ras1, and c-erbB-2 proto-oncogenes were expressed in proliferating normal cells. This level of expression was compared with that of primary tumor cells, malignant effusion cells, or permanently established breast cancer cell lines. Pure preparations of epithelial organoids from seven different reduction mammoplasty tissue samples yielded proliferating normal epithelial cells upon short-term tissue culture. In every sample, proto-oncogene transcript levels increased upon short-term culture of the epithelial cells. These levels often exceeded by 10-fold the levels measured in uncultured organoids from the same tissue. In four of the seven cultured normal breast samples, at least one of the proto-oncogenes increased its expression to a level equaling or exceeding that found in a proliferating breast cancer cell line, MCF7. One effusion metastasis sample and two primary ductal adenocarcinomas were also examined for proto-oncogene expression. The effusion metastasis sample expressed high levels of c-erbB-2 messenger RNA, in accord with its amplified gene copy number; otherwise, the levels of proto-oncogene transcripts were low in unprocessed tumor and uncultured organoids, but they increased with proliferation of the tumor cells in culture. These results indicate that the variable expression of these proto-oncogenes observed in breast biopsy specimens needs to be controlled for cellular growth rate or proliferation index. Furthermore, these findings suggest that dysregulated proto-oncogene expression, rather than overexpression per se, needs to be evaluated as a possible mechanism contributing to the development of human breast cancer.
Benz
C C
CC
Cancer Research Institute, University of California, San Francisco 94143.
Scott
G K
GK
Santos
G F
GF
Smith
H S
HS
D015152:Blotting, Northern; D001940:Breast / Q000166:cytology / Q000473:pathology; D001943:Breast Neoplasms / Q000032:analysis / Q000235:genetics* / Q000473:pathology; D002460:Cell Line; D002478:Cells, Cultured; D004847:Epithelial Cells; D004848:Epithelium / Q000032:analysis / Q000473:pathology; D005260:Female; D015870:Gene Expression; D006801:Humans; D000090063:Proto-Oncogene Mas; D011518:Proto-Oncogene Proteins; D016271:Proto-Oncogene Proteins c-myc; D016283:Proto-Oncogene Proteins p21(ras); D012334:RNA, Neoplasm / Q000302:isolation & purification; D018719:Erb-b2 Receptor Tyrosine Kinases; D014157:Transcription Factors / Q000235:genetics
D000090063:Proto-Oncogene Mas; D011518:Proto-Oncogene Proteins; D016271:Proto-Oncogene Proteins c-myc; D016283:Proto-Oncogene Proteins p21(ras); D012334:RNA, Neoplasm; D018719:Erb-b2 Receptor Tyrosine Kinases; D014157:Transcription Factors; C000715470:MAS1 protein, human; C501009:HRAS protein, human